Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DME (ID: DE0P6LK)

• DME Name: Sulfotransferase 2A1 (SULT2A1) DME Info
• Gene Name: SULT2A1

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abiraterone acetate	DMANBZI	Prostate cancer	2C82.0	Approved	[1]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[2]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[3]
Pregnenolone	DM6VFO1	Schizophrenia	6A20	Phase 4	[4]

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[5]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[2]
BCP-13498	DM2BO9W	N. A.	N. A.	Phase 2	[6]

4 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[2]
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[2]
N-nonylphenol	DMH3OUX	N. A.	N. A.	Investigative	[2]
Tetramethylbutylphenol	DMW9CH2	N. A.	N. A.	Investigative	[2]

References

• [1] Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
• [2] Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
• [3] In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
• [4] Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
• [5] Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
• [6] Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.